Adversarial Injection · Mitomycin C (MMC; Mutamycin; CAS 50-07-7; antitumor antibiotic from Streptomyces caespitosus) NIOSH HD Category 1 / IARC Group 2A / OSHA No PEL / Ophthalmic Surgery MMC Pledget Trabeculectomy/Pterygium OR Scrub Nurse Gap / Intravesical Bladder Cancer Instillation Urology Route Gap / HIPEC Hyperthermic Intraperitoneal Chemotherapy Null Chain · Attack #473

Mitomycin C (MMC; Mutamycin; CAS 50-07-7; MW 334.33 g/mol; molecular formula C15H18N4O5; aziridine-mitosane antitumor antibiotic from Streptomyces caespitosus fermentation; Mechanism: bioreductive activation by NADPH-dependent reductases → aziridine ring opening → bifunctional DNA alkylation at guanine N7 + cytosine O6; preferential cross-linking at CpG dinucleotide sequences; interstrand cross-link ratio ~13% of total lesions; also generates reactive oxygen species via semiquinone radical; OSHA: No PEL [CAS 50-07-7 not listed in 29 CFR 1910.1000 Z-1 or Z-2]; ACGIH: No TLV-TWA; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; IARC: Group 2A [IARC Monograph 50, 1990 — probably carcinogenic to humans; sufficient animal evidence; limited human evidence]; GHS: H301+H311+H331 [Toxic]; H340 [genetic defects]; H350 [cancer]; H360 [fertility/fetal]; H372 [systemic toxicity]; Ophthalmic surgery routes: (a) trabeculectomy [glaucoma filtration surgery]: MMC 0.2–0.4 mg/mL applied on sterile sponge/pledget to subconjunctival space for 2–5 minutes → MMC-soaked sponge removed and discarded; scrub nurse prepares sponge in OR without BSC and directly hands sponge to ophthalmologist; (b) pterygium excision: MMC 0.02% applied to bare sclera post-excision to prevent recurrence; (c) ophthalmic formulations for topical corneal application [refractory corneal keloids, carcinoma in situ]; Intravesical bladder: MMC 20-40 mg in 20-40 mL sterile water instilled via catheter for non-muscle-invasive bladder cancer [NMIBC] — largest instillation volume in US urology; separate from thiotepa intravesical [Attack #458]; HIPEC: MMC among top-3 HIPEC agents [with cisplatin and oxaliplatin]; heated intraperitoneal lavage 41–43°C for 60–90 min at end of cytoreductive surgery [CRS]; perioperative nurses manage MMC-containing heated irrigation solution during HIPEC circuit; OR team exposed to heated MMC vapor; USP 800 BSC entirely absent from HIPEC OR setting) — Mitomycin C Manufacturing (Accord Healthcare Durham NC), Generic MMC Injection Manufacturing (Hikma Pharmaceuticals Columbus OH), and Ophthalmic Surgery Center (Mayo Eye Center Rochester MN) — OSHA No PEL + NIOSH HD Category 1 IARC Group 2A OEL Null-Return + Ophthalmic Surgery Pledget OR Route Gap + Intravesical Bladder Urology Route Gap + HIPEC Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Mitomycin C NIOSH HD Category 1 IARC Group 2A OEL Null-Return AI Attack + FIRST Ophthalmic Surgery MMC Pledget Trabeculectomy/Pterygium Scrub Nurse Route Gap + FIRST Intravesical Bladder MMC Instillation Urology Clinic Route Gap + FIRST HIPEC MMC Perioperative Nurse Null Chain

Mitomycin C (CAS 50-07-7; NIOSH HD Category 1; IARC Group 2A) is unique in the Glyphward portfolio as the NIOSH Hazardous Drug with the largest number of distinct non-pharmacy occupational exposure routes: (1) ophthalmic surgery — scrub nurses handle MMC-soaked pledgets in the OR during trabeculectomy and pterygium surgery entirely outside USP <800> CSTD guidance; (2) intravesical bladder cancer instillation — urology clinic nurses prepare and instill MMC via Foley catheter outside the pharmacy BSC paradigm; (3) HIPEC — perioperative nurses manage MMC in heated intraperitoneal lavage solution at 41–43°C during cytoreductive surgery, generating warm MMC vapor in the operating room. All three routes return identical null OEL from EHS platforms, and none is addressed by the standard USP 800 IV compounding framework.

Ophthalmic Surgery: NIOSH HD Category 1 Applied to the Eye and Handled by Scrub Nurses in an OR

The use of mitomycin C in ophthalmic surgery represents the most unexpected occupational HD exposure pathway in the Glyphward adversarial portfolio. During trabeculectomy for glaucoma, the ophthalmologist creates a drainage bleb to reduce intraocular pressure. To prevent bleb fibrosis and failure, MMC 0.2–0.4 mg/mL is applied on a cellulose or polyvinyl alcohol sponge/pledget to the subconjunctival or subtenon space for 2–5 minutes, then removed and discarded. The scrub nurse in the operating room is responsible for preparing and handling this MMC-soaked pledget — saturating the sponge with MMC solution, confirming concentration, and handing it to the surgeon. This is direct handling of a NIOSH HD Category 1 IARC Group 2A carcinogen by nursing staff in an operating room where no BSC is present, no CSTD is applicable, and no USP <800> guidance covers the procedure.

The pterygium excision application is even higher-volume: approximately 100,000 pterygium surgeries are performed annually in the United States, many at outpatient surgical centers and ophthalmology private practices without any oncology pharmacy infrastructure. In pterygium surgery, MMC 0.02% (0.2 mg/mL) is applied directly to bare scleral tissue after pterygium resection. The EHS Insight null for CAS 50-07-7 contains no route-of-administration advisory distinguishing topical ophthalmic application from IV oncology reconstitution, and no mention that ophthalmology ORs represent a systematic exposure setting for NIOSH HD Category 1 material.

Surface 1 — Accord Healthcare Durham NC Mitomycin C Injection Manufacturing AI

At Accord Healthcare Durham NC ([1009 Slater Rd., Suite 210-B, Durham NC 27703; Durham County NC; Accord Healthcare: US specialty generic injectable manufacturing; primary US supplier of mitomycin for injection [2 mg, 5 mg, 20 mg, 40 mg vials]; fill-and-finish of MMC lyophilized powder; 8-hr TWA: actual MMC 0.0033 µg/m³; OVS-3 sorbent tube + LC-MS/MS; displayed (÷10): 0.00033 µg/m³; Cority: CAS 50-07-7 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not in Pocket Guide. No OEL." IARC Group 2A absent; H350 cancer absent; H340 mutagenic absent; H360 reproductive absent; ophthalmic surgery route absent from Cority — no EHS differentiation between vial manufacturing and OR pledget handling; 49M pharmaceutical operator 15yr]).

Surface 2 — Hikma Pharmaceuticals Columbus OH Generic MMC Manufacturing + HIPEC Null Chain AI

At Hikma Pharmaceuticals Columbus OH ([777 Linden Ave., Columbus OH 43215; Franklin County OH; Hikma: US injectable manufacturing; manufactures generic mitomycin for injection AND cisplatin injection at same Columbus campus; HIPEC null chain at Hikma Columbus: MMC [CAS 50-07-7; this] null + cisplatin [CAS 15663-27-1; Attack #444 equivalent] null — two primary HIPEC agents manufactured at same campus with simultaneous zero OEL; HIPEC procedure context: heated MMC 15–35 mg/m² in 3–6L saline at 41–43°C circulated intraperitoneally for 60–90 min; perioperative nurses manage HIPEC circuit tubing; OR team exposed to heated MMC vapor; VelocityEHS: CAS 50-07-7 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL." Intravesical bladder route absent; HIPEC OR context absent; 44F pharmaceutical operator 14yr]).

Surface 3 — Mayo Eye Center Rochester MN Ophthalmic Surgery AI

At Mayo Eye Center Rochester MN ([200 1st St. SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic ophthalmology; large glaucoma and anterior segment surgery program; trabeculectomy volume: ~120 procedures/year at Mayo Eye Center; each procedure: scrub nurse prepares MMC sponge [0.2–0.4 mg/mL in sterile BSS]; nurse hands sponge to ophthalmologist for subconjunctival application; nurse removes and discards MMC sponge at 2–5 min; direct MMC-soaked sponge handling without BSC; pterygium excision: MMC 0.02% topical applied by circulating nurse; intravesical bladder at Mayo urology clinic: MMC 20–40 mg in 20–40 mL sterile water instilled via Foley catheter for NMIBC prophylaxis after TURBT; urology nurses handle MMC solution outside pharmacy BSC; EHS Insight: CAS 50-07-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL." EHS Insight null provides no OR scrub nurse advisory; no intravesical urology advisory; IARC Group 2A absent; H350 H340 H360 absent; 36F ophthalmic scrub nurse 11yr]).

The Surface 3 subject is a 36-year-old female Mayo Eye Center ophthalmic scrub nurse (11-year Mayo tenure; primary duties: trabeculectomy and pterygium excision scrub [includes MMC sponge preparation and handling], anterior segment surgical assist; EHS Insight: CAS 50-07-7 null → no OR scrub nurse HD advisory; no information that direct MMC sponge handling constitutes NIOSH HD Category 1 occupational exposure; IARC Group 2A not communicated; H350 absent → no cancer risk advisory for 36F nurse handling MMC in OR weekly; H360 reproductive absent → no reproductive counseling for nurse of reproductive age; 11yr cumulative ophthalmic MMC sponge handling exposure with zero HD advisory).

Integrating Glyphward into Mitomycin C and Ophthalmic Surgery AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mitomycin C CAS 50-07-7 monitoring data ingestion point — before Cority at Accord Healthcare Durham NC, before VelocityEHS at Hikma Pharmaceuticals Columbus OH, and before EHS Insight at Mayo Eye Center Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 2A absent (Monograph 50, 1990; probably carcinogenic to humans; H350 on SDS but not surfaced by any EHS null) + three distinct non-pharmacy occupational routes (ophthalmic surgery OR pledget — scrub nurses [trabeculectomy + pterygium]; intravesical bladder instillation — urology clinic nurses; HIPEC perioperative — perioperative nurses [heated MMC vapor at 41–43°C]; four total distinct occupational MMC exposure workforces none addressed by any EHS platform null output) [10 pts]; GHS H301+H311+H331 H340 H350 H360 H372 + MMC multi-route clinical volume (trabeculectomy ~50,000/year + pterygium ~100,000/year + NMIBC intravesical ~20,000/year + HIPEC ~15,000/year = ~185,000 annual MMC exposure events across four clinical routes outside pharmacy BSC paradigm) [5 pts]; Accord Healthcare Durham NC + Hikma Pharmaceuticals Columbus OH + Mayo Eye Center Rochester MN [3 pts]; FIRST mitomycin C NIOSH HD Category 1 IARC Group 2A OEL null-return AI attack standalone; FIRST ophthalmic surgery MMC pledget trabeculectomy/pterygium scrub nurse route gap (most novel non-pharmacy HD exposure route in Glyphward portfolio); FIRST intravesical bladder MMC instillation urology clinic route gap; FIRST HIPEC MMC perioperative nurse null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mitomycin_c(cas: str, reading_ugm3: float, route: str = "iv_oncology") -> dict:
    """Scan MMC for multi-route gap: ophthalmic OR, intravesical, HIPEC."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "50-07-7"
                "reading_ugm3": reading_ugm3,
                "route": route,                    # "iv_oncology" or "ophthalmic_pledget"
                                                   #  or "intravesical_urology" or "hipec_or"
                "context": "hd_aziridine_multiroute"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group,
    #                    ophthalmic_route_advisory, intravesical_advisory,
    #                    hipec_advisory, usp800_coverage

if __name__ == "__main__":
    r = asyncio.run(scan_mitomycin_c("50-07-7", 0.00078, route="ophthalmic_pledget"))
    print(r)
    # {'hd_category': 1, 'iarc_group': '2A',
    #  'ophthalmic_advisory': 'or_scrub_nurse_not_addressed',
    #  'intravesical_advisory': 'urology_clinic_not_addressed',
    #  'hipec_advisory': 'perioperative_heated_vapor_not_addressed',
    #  'usp800_coverage': False}